Biosurveillance & bioWatch generation-3 acquisition
Intro -- BIOSURVEILLANCE AND BIOWATCH GENERATION-3 ACQUISITION -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1: Biosurveillance: DHS Should Reevaluate Mission Need and Alternatives before Proceeding with BioWatch Generation-3 Acquisition( -- Why GAO Did This Study -- What GAO Recommends -- What GAO Found -- Abbreviations -- Background -- BioWatch and the Biodefense Enterprise -- BioWatch Past and Present -- BioWatch in Action -- Gen-3 Development and Challenges -- DHS's Four-Phase Acquisition Life-cycle Framework -- DHS Did Not Fully Develop Critical Information for Initial Investment Decision Making -- DHS Did Not Use Acquisition Life-cycle Framework Processes to Identify a Justified Mission Need -- DHS Did Not Use Acquisition Life-cycle Processes to Analyze Alternatives Based on Cost, Schedule, and Risk to Identify an Optimal Solution -- DHS Did Not Develop Complete and Reliable Performance, Schedule, and Cost Information before Approving the Gen-3 Acquisition -- BioWatch Must Demonstrate System Performance and Receive Approval before -- Full Deployment, Estimated for 2022 -- Conclusions -- Recommendations for Executive Action -- Agency Comments and Our Evaluation -- Appendix I. Limitations of Gen-3 Acquisition Documents and -- Processes at ADE-2A -- Appendix II. BioWatch Gen-3 Characterization Test Events and Candidate Technology Performance against Key Performance Parameters -- End Notes -- Chapter 2: Statement of Gus Bilirakis, Chairman, Subcommittee on Emergency Preparedness, Response, and Communications. Hearing on "BioWatch Present and Future: Meeting Mission Needs for Effective Biosurveillance?"(.